Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CeTeG: CCNU/TMZ vs Standard TMZ in MGMT-methylated Glioblastoma
NCT01149109Phase 3Completed
- Sponsor
- University Hospital Bonn
- Start
- Oct 2010
- Primary completion
- Apr 2017
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lomustine in glioblastoma (GBM) (2 arms), sponsored by University Hospital Bonn. Primary endpoint: Overall Survival at 4 years. Started Oct 2010; status: completed.
02
Drugs
lomustine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01149109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01149109.